Raymond Elsey - Regenerx Biopharm Independent Director
| RGRXDelisted Stock | USD 0.0009 0.0001 12.50% |
Director
Mr. Raymond Donald Elsey is Independent Director of the Company. Currently Mr. Elsey serves as CFO of Senseonics, Inc. a medical device company focused on continuous glucose monitoring. From May 2014 until February 2015 Mr. Elsey served as chief financial officer of Regado Biosciences, a public, latestage clinical development biopharmaceutical company. From December 2012 to February 2014 Mr. Elsey served as chief financial officer of LifeCell, Inc., a privately held regenerative medicine company. From June 2005 to December 2012, he served in numerous finance capacities, most recently as senior vice president and chief financial officer, at Emergent BioSolutions Inc., a publicly held biopharmaceutical company. He served as the director of finance and administration at IGEN International, Inc., a publicly held biotechnology company, and its successor BioVeris Corporationrationration, from April 2000 to June 2005. Prior to joining IGEN, Mr. Elsey served as director of finance at Applera, a genomics and sequencing company, and in several finance positions at International Business Machines, Inc. He received an M.B.A. in finance and a B.A. in economics from Michigan State University. Mr. Elsey is a certified management accountant. The Board believes that Mr. Elseys experience as chief financial officer of a public company is particularly valuable to our business in that it positions him to contribute to our boards and audit committees understanding of financial matters. since 2010.
| Age | 63 |
| Tenure | 14 years |
| Phone | 301 208 9191 |
| Web | https://www.regenerx.com |
Regenerx Biopharm Management Efficiency
The company has return on total asset (ROA) of (0.8397) % which means that it has lost $0.8397 on every $100 spent on assets. This is way below average. Regenerx Biopharm's management efficiency ratios could be used to measure how well Regenerx Biopharm manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.14 M in liabilities. Regenerx Biopharm has a current ratio of 1.03, suggesting that it may have difficulties to pay its financial obligations when due. Debt can assist Regenerx Biopharm until it has trouble settling it off, either with new capital or with free cash flow. So, Regenerx Biopharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regenerx Biopharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regenerx to invest in growth at high rates of return. When we think about Regenerx Biopharm's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | DIRECTOR Age | ||
| Malcolm Hoenlein | Fortress Biotech Pref | 73 | |
| Todd Caven | Regen BioPharma | 52 | |
| Jimmie Harvey | Fortress Biotech Pref | 62 | |
| Jay Lobell | Fortress Biotech Pref | 51 | |
| Kevin Lorenz | Fortress Biotech Pref | N/A | |
| David Barrett | Fortress Biotech Pref | 39 | |
Management Performance
| Return On Asset | -0.84 |
Regenerx Biopharm Leadership Team
Elected by the shareholders, the Regenerx Biopharm's board of directors comprises two types of representatives: Regenerx Biopharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regenerx. The board's role is to monitor Regenerx Biopharm's management team and ensure that shareholders' interests are well served. Regenerx Biopharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regenerx Biopharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| J Finkelstein, CEO and President and Director | ||
| Nabila Turjman, Ex Affairs | ||
| Don Elsey, Independent Director | ||
| Allan Goldstein, Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board | ||
| Alessandro Noseda, Director | ||
| Joseph McNay, Independent Director | ||
| Raymond Elsey, Independent Director | ||
| Mauro Bove, Independent Director |
Regenerx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Regenerx Biopharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.84 | ||||
| Operating Margin | (19.03) % | ||||
| Current Valuation | 22.91 M | ||||
| Shares Outstanding | 143.55 M | ||||
| Shares Owned By Insiders | 45.99 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 19.19 K | ||||
| Price To Earning | 17.73 X | ||||
| Price To Sales | 261.81 X | ||||
| Revenue | 76.76 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regenerx Biopharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regenerx Biopharm's short interest history, or implied volatility extrapolated from Regenerx Biopharm options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Regenerx OTC Stock
If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |